Literature DB >> 14734051

Inducibility of life-threatening ventricular arrhythmias is related to maximum left ventricular thickness and clinical markers of sudden cardiac death in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene.

A Hedman1, J Hartikainen, E Vanninen, T Laitinen, P Jääskeläinen, M Laakso, K Peuhkurinen, J Kuusisto.   

Abstract

We investigated inducibility of life-threatening arrhythmias with programmed ventricular stimulation (PVS) in relation to clinical markers of sudden cardiac death (SCD) in subjects with hypertrophic cardiomyopathy (HCM) attributable to the Asp175Asn mutation in the alpha-tropomyosin gene (TPM1-Asp175Asn). PVS was performed with up to three extrastimuli and distribution of markers of SCD was evaluated in 21 adult subjects with the TPM1-Asp175Asn. Sustained polymorphic ventricular tachycardia (VT) or ventricular fibrillation (VF) was induced in seven of 21 subjects (33%). Inducible subjects had more severe left ventricular hypertrophy (LVH) and an increased number of markers of SCD (family history of SCD, syncope or presyncope, fall in systolic blood pressure (BP) during exercise, documented non-sustained VT (NSVT), and marked LVH) compared to non-inducible subjects (IVS 2.4 +/- 0.3 cm vs. 1.6 +/- 0.5 cm, P < 0.001; and two to three vs. one to two markers of SCD, P = 0.007, respectively). In conclusion, in HCM attributable to the Asp175Asn mutation in the alpha-tropomyosin gene, life-threatening arrhythmias were induced in one third of the patients. Inducibility was associated with the maximum left ventricular (LV) thickness and the number of markers of SCD, suggesting that in HCM patients with an identical causative mutation, susceptibility to ventricular arrhythmias is related to the cardiomyopathic phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734051     DOI: 10.1016/j.yjmcc.2003.10.003

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

1.  Functional effects of a tropomyosin mutation linked to FHC contribute to maladaptation during acidosis.

Authors:  Katherine A Sheehan; Grace M Arteaga; Aaron C Hinken; Fernando A Dias; Cibele Ribeiro; David F Wieczorek; R John Solaro; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2010-11-01       Impact factor: 5.000

2.  Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: a positron emission tomography study.

Authors:  Helena Tuunanen; Johanna Kuusisto; Jyri Toikka; Pertti Jääskeläinen; Päivi Marjamäki; Keijo Peuhkurinen; Tapio Viljanen; Petri Sipola; Kira Q Stolen; Jarna Hannukainen; Pirjo Nuutila; Markku Laakso; Juhani Knuuti
Journal:  J Nucl Cardiol       Date:  2007-05-10       Impact factor: 5.952

3.  Arrhythmia caused by a Drosophila tropomyosin mutation is revealed using a novel optical coherence tomography instrument.

Authors:  Lisha Ma; Adrian Bradu; Adrian Gh Podoleanu; James W Bloor
Journal:  PLoS One       Date:  2010-12-17       Impact factor: 3.240

4.  Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy.

Authors:  Johanna Kuusisto; Vesa Kärjä; Petri Sipola; Ivana Kholová; Keijo Peuhkurinen; Pertti Jääskeläinen; Anita Naukkarinen; Seppo Ylä-Herttuala; Kari Punnonen; Markku Laakso
Journal:  Heart       Date:  2012-03-24       Impact factor: 5.994

5.  Divergent effects of adrenaline in human induced pluripotent stem cell-derived cardiomyocytes obtained from hypertrophic cardiomyopathy.

Authors:  Chandra Prajapati; Marisa Ojala; Katriina Aalto-Setälä
Journal:  Dis Model Mech       Date:  2018-02-26       Impact factor: 5.758

6.  Heterozygous junctophilin-2 (JPH2) p.(Thr161Lys) is a monogenic cause for HCM with heart failure.

Authors:  Sari U M Vanninen; Krista Leivo; Eija H Seppälä; Katriina Aalto-Setälä; Olli Pitkänen; Piia Suursalmi; Antti-Pekka Annala; Ismo Anttila; Tero-Pekka Alastalo; Samuel Myllykangas; Tiina M Heliö; Juha W Koskenvuo
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240

7.  Genetic basis and outcome in a nationwide study of Finnish patients with hypertrophic cardiomyopathy.

Authors:  Pertti Jääskeläinen; Jagadish Vangipurapu; Joose Raivo; Teemu Kuulasmaa; Tiina Heliö; Katriina Aalto-Setälä; Maija Kaartinen; Erkki Ilveskoski; Sari Vanninen; Liisa Hämäläinen; John Melin; Jorma Kokkonen; Markku S Nieminen; Markku Laakso; Johanna Kuusisto
Journal:  ESC Heart Fail       Date:  2019-02-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.